Jafron Biomedical Co (SZSE:300529) YoY EBITDA Growth : 64.91% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Jafron Biomedical Co's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 64.91%.

Jafron Biomedical Co's EBITDA per Share for the three months ended in Sep. 2024 was ¥0.38.

Jafron Biomedical Co YoY EBITDA Growth Historical Data

The historical data trend for Jafron Biomedical Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co YoY EBITDA Growth Chart

Jafron Biomedical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

40.54

46.61

41.20

-21.80

-38.85

Jafron Biomedical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
YoY EBITDA Growth	Get a 7-Day Free Trial															29.55	67.86	45.18	209.70	64.91

Jafron Biomedical Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Jafron Biomedical Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(0.875	-	1.431)	/	\| 1.431 \|
=	-38.85 %

Jafron Biomedical Co's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

	YoY EBITDA Growth (Q: Sep. 2024 )
=	(EBITDA per Share (Q: Sep. 2024 )	-	EBITDA per Share (Q: Sep. 2023 ))	/	\| EBITDA per Share (Q: Sep. 2023 )) \|
=	(0.376	-	0.228)	/	\| 0.228 \|
=	64.91 %

Jafron Biomedical Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Jafron Biomedical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085

Website

http://www.jafron.com

Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.

Executives

Li Feng	Director
He Xiao Lian	Executives
Dong Fan	Directors, Directors, and Executives
Ceng Kai	Directors, executives
Tang Xian Min	Directors, executives
Zhang Ming Yuan	Secretary Dong
Fang Li Hua	Supervisors
Zhang Guang Hai	Directors, executives
Li De Zhi	Executives
Lu Shao Zhang	Executives

Jafron Biomedical Co Headlines

No Headlines